| answer text |
<p>Commitments in the current voluntary scheme for branded medicines pricing and access
around patient access and uptake for innovative medicines have had a substantial positive
impact on the speed of medicines access in England, ensuring that National Health
Service patients benefit from cutting-edge treatments including personalised CAR-T
cancer therapies, lifechanging treatments for rare conditions, and lifesaving gene
therapies. The new voluntary scheme for branded medicines pricing, access and growth
agreement will continue to build on these significant achievements, for example, through
the piloting of new approaches for paying for ground-breaking advanced therapy medicinal
products.</p><p>We do not expect disproportional impacts on people with less common
conditions resulting from these policies. Provisions in the scheme allow for companies
to apply for price increases should supply of products be otherwise uneconomical.
Under specific circumstances an adjusted ‘Top-up Payment Percentage’ can also be considered
for other older medicines where there would otherwise be a negative impact on patients.</p>
|
|
